ORNBV Stock Analysis: Orion | HE
Drug Manufacturers - General | HE, Finland | Market Cap: 11.051m EUR | 12M Return: 16.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 12.2M
EPS Trend: 95.5%
Qual. Beats: 0
Rev. Trend: 98.6%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Orion Oyj is a Finland-based pharmaceutical company founded in 1917 and headquartered in Espoo, developing, manufacturing, and marketing human and veterinary pharmaceuticals as well as active pharmaceutical ingredients (APIs) across Europe, North America, and other international markets. Its human pharma portfolio spans oncology (Nubeqa for prostate cancer, Fareston for breast cancer), neurology (Parkinsons treatments such as Entacapone, Stalevo, Comtess, Comtan), respiratory care (the Easyhaler device family for asthma and COPD), and critical care (Dexdor/Precedex for sedation, Simdax for acute decompensated heart failure), alongside self-care products sold online. The veterinary segment offers sedatives and related drugs (Domosedan, Dexdomitor, Sileo, among others), and the company also provides contract manufacturing for APIs and proprietary products. Key partnerships include a co-development and commercialisation agreement with Bayer for darolutamide (Nubeqa) and a licensing deal with Tenax Therapeutics to develop oral levosimendan (TNX-103) for pulmonary hypertension in heart failure with preserved ejection fraction.
Orion trades on the Helsinki Stock Exchange under the ticker ORNBV (Class B share), reflecting the Finnish two-class share structure common among major Nordic listed companies, where B shares typically carry lower voting rights and greater liquidity than A shares. As a pharmaceuticals manufacturer with proprietary R&D, generics, and animal health operations, Orion is a relatively diversified mid-sized player in the European pharma sector, less concentrated in a single therapy area than many specialty pharma peers.
- Nubeqa royalties from Bayer partnership accelerate prostate cancer sales
- Easyhaler respiratory portfolio gains European market share
- Generic erosion pressures Entacapone Parkinsons franchise margins
| Net Income: 587.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.21 > 0.02 and ΔFCF/TA 7.49 > 1.0 |
| NWC/Revenue: 36.21% < 20% (prev 27.83%; Δ 8.37% < -1%) |
| CFO/TA 0.25 > 3% & CFO 471.6m > Net Income 587.1m |
| Net Debt (17.1m) to EBITDA (796.3m): 0.02 < 3 |
| Current Ratio: 2.64 > 1.5 & < 3 |
| Outstanding Shares: last quarter (140.9m) vs 12m ago 0.74% < -2% |
| Gross Margin: 65.93% > 18% (prev 61.84%; Δ 4.09% > 0.5%) |
| Asset Turnover: 116.9% > 50% (prev 101.9%; Δ 15.03% > 0%) |
| Interest Coverage Ratio: 194.7 > 6 (EBIT TTM 740.0m / Interest Expense TTM 3.80m) |
| A: 0.40 (Total Current Assets 1.20b - Total Current Liabilities 454.5m) / Total Assets 1.87b |
| B: 0.62 (Retained Earnings 1.17b / Total Assets 1.87b) |
| C: 0.42 (EBIT TTM 740.0m / Avg Total Assets 1.76b) |
| D: 2.10 (Book Value of Equity 1.27b / Total Liabilities 604.7m) |
| Altman-Z'' = 9.67 = AAA |
| DSRI: 1.18 (Receivables 543.8m/374.9m, Revenue 2.06b/1.68b) |
| GMI: 0.94 (GM 61.84% / 65.93%) |
| AQI: 0.89 (AQ_t 0.11 / AQ_t-1 0.13) |
| SGI: 1.23 (Revenue 2.06b / 1.68b) |
| TATA: 0.06 (NI 587.1m - CFO 471.6m) / TA 1.87b) |
| Beneish M = -2.83 (Cap -4..+1) = A |
As of July 28, 2026, the stock is trading at EUR 79.55 with a total of 165,035 shares traded. Over the past week, the price has changed by +5.78%, over one month by +11.96%, over three months by +17.42% and over the past year by +16.67%.
Current recommended Stop Loss: 77.00 (which is 3.2% or 1.2 ATR below the current price).
Orion has no consensus analysts rating.
P/E Trailing = 18.7679
P/E Forward = 29.4985
P/S = 5.3703
P/B = 8.7812
P/EG = 5.7296
Revenue TTM = 2.06b EUR
EBIT TTM = 740.0m EUR
EBITDA TTM = 796.3m EUR
Long Term Debt = 105.9m EUR (from longTermDebt, last fiscal year)
Short Term Debt = 29.3m EUR (from shortTermDebt, last quarter)
Debt = 147.3m EUR (from shortLongTermDebtTotal, last quarter) + Leases 14.6m
Net Debt = 17.1m EUR (calculated: Debt 147.3m - CCE 130.2m)
Enterprise Value = 11.1b EUR (11.1b + Debt 147.3m - CCE 130.2m)
Interest Coverage Ratio = 194.7 (Ebit TTM 740.0m / Interest Expense TTM 3.80m)
EV/FCF = 28.48x (Enterprise Value 11.1b / FCF TTM 388.6m)
FCF Yield = 3.51% (FCF TTM 388.6m / Enterprise Value 11.1b)
FCF Margin = 18.89% (FCF TTM 388.6m / Revenue TTM 2.06b)
Net Margin = 28.54% (Net Income TTM 587.1m / Revenue TTM 2.06b)
Gross Margin = 65.93% ((Revenue TTM 2.06b - Cost of Revenue TTM 701.0m) / Revenue TTM)
Gross Margin QoQ = 65.16% (prev 60.81%)
Tobins Q-Ratio = 5.91 (Enterprise Value 11.1b / Total Assets 1.87b)
Interest Expense / Debt = 2.58% (Interest Expense 3.80m / Debt 147.3m)
Taxrate = 20.31% (149.6m / 736.6m)
NOPAT = 589.7m (EBIT 740.0m * (1 - 20.31%))
Current Ratio = 2.64 (Total Current Assets 1.20b / Total Current Liabilities 454.5m)
Debt / Equity = 0.12 (Debt 147.3m / totalStockholderEquity, last quarter 1.27b)
Debt / EBITDA = 0.02 (Net Debt 17.1m / EBITDA 796.3m)
Debt / FCF = 0.04 (Net Debt 17.1m / FCF TTM 388.6m)
Total Stockholder Equity = 1.17b (last 4 quarters mean from totalStockholderEquity)
RoA = 33.36% (Net Income 587.1m / Total Assets 1.87b)
RoE = 50.02% (Net Income TTM 587.1m / Total Stockholder Equity 1.17b)
RoCE = 57.83% (EBIT 740.0m / Capital Employed (Equity 1.17b + L.T.Debt 105.9m))
RoIC = 43.83% (NOPAT 589.7m / Invested Capital 1.35b)
WACC = 6.93% (E(11.1b)/V(11.2b) * Re(7.0%) + D(147.3m)/V(11.2b) * Rd(2.58%) * (1-Tc(0.20)))
Discount Rate = 7.0% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 10.77 | Cagr: 0.14%
[DCF] Terminal Value 77.97% ; FCFF base≈320.4m ; Y1≈367.2m ; Y5≈540.5m
[DCF] Fair Price = 74.13 (EV 8.13b - Net Debt 17.1m = Equity 8.12b / Shares 109.5m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 95.54 | EPS CAGR: 50.14% | SUE: 0.15 | # QB: 0
Revenue Correlation: 98.55 | Revenue CAGR: 24.36% | SUE: 0.35 | # QB: 0
EPS current Quarter (2026-09-30): EPS=1.06 | Chg30d=-5.31% | Revisions=+25% | Analysts=4
EPS current Year (2026-12-31): EPS=4.06 | Chg30d=+3.99% | Revisions=+40% | GrowthEPS=+14.1% | GrowthRev=+10.8%
EPS next Year (2027-12-31): EPS=4.68 | Chg30d=+1.41% | Revisions=+40% | GrowthEPS=+15.1% | GrowthRev=+12.4%
[Analyst] Revisions Ratio: +62% (up=5, down=0)